Trial Profile
A randomised, Phase 1, double-blind, placebo-controlled single and multiple ascending dose study to assess the safety, tolerability and pharmockinetics of PBT434 in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Nov 2021
Price :
$35
*
At a glance
- Drugs ATH 434 (Primary)
- Indications Multiple system atrophy; Parkinson's disease
- Focus Adverse reactions; First in man
- Acronyms PBT434-101
- Sponsors Alterity Therapeutics
- 09 Nov 2021 According to an Alterity Therapeutics media release, data from the study has been presented at the American Autonomic Society 32nd Annual International Symposium on the Autonomic Nervous System 2021.
- 09 Nov 2021 Results presented in an Alterity Therapeutics media release.
- 16 Sep 2020 Results assessing cardiac liability of PBT434 using concentration-response and outlier analyses of ECG and pharmacokinetic (PK) data from this study, presented at the 24th International Congress of Parkinson's Disease and Movement Disorders.